1Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med, 2002, 346: 645-652.
2Barrett J. Allogeneic stem cell transplantation for chronic myeloid leukemia. Semin Hematol, 2003, 40: 59-71.
3Koh LP, Hwang WY, Tan CH, et al. Long term follow-up of Asian patients with chronic myeloid leukemia (CML) receiving allogeneic hematopoietic stem cell transplantation (HSCT) from HLA-identical sibling: evaluation of risks and benefits. Ann Hematol, 2004, 83:286-294.
4Kanda Y, Chiba S, Hirai H, et al. Allogenic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade (1991-2000). Blood, 2003, 102:1541-1547.
5Socie G, Clift RA, Blaise D, et al. Busulfan plus eyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood, 2001, 98:3569-3574.
6Qazilbash MH, Devetten MP, Abraham J, et al. Utility of a prognostic scoring system for allogeneic stem cell transplantation in patients with chronic myeloid leukemia. Aeta Haematol, 2003, 109:119-123.
7Copelan EA, Penza SL, Theil KS, et al. The influence of early transplantation, age, GVHD prevention regimen, and other factors on outcome of allogeneic transplantation for CML following BuCy.Bone Marrow Transplant, 2000, 26: 1037-1043.
8Weisdorf DJ, Anasetti C, Antin JH, et al. Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation.Blood, 2002, 99: 1971-1977.
